Eric lefkofsky is the Co-founder of Tempus and currently lives in Chicago, USA. Tempus is a biotechnology organization that deals in the therapy of cancer convalescents. Additionally, the company also investigates therapeutic and molecular information and distributes genomic sequencing services helping doctors to make real-time, information-driven conclusions. Also, the main aim of the Tempus is to modernize cancer therapy, enabling convalescents to get treatment according to the data obtained from previous patients. This, therefore, improves the quality of services being provided by the firm. As the CEO, Eric is devoted to spreading the organization’s influence locally, nationally, and internationally. Besides, Mr Lefkofsky is also dedicated to bettering the firm’s expertise on the treatment of cancer. Consequently, increasing the company’s impact on the society.
Other than Tempus, Eric Lefkofsky has also co-founded other organizations. These organizations include Echo Global Logistics (a key provider of technology-enabled transportation, and supply chain management service), and lightbank (a capital company dealing in investments in disruptive technology firms). Also, others include Groupon (a worldwide e-commerce marketplace), and InnerWorkings (a service provider in print media). Apart from business activities, Eric is also a philanthropist using most of his resources on various charitable endeavors. In 2006, Eric Lefkofsky founded the Lefkofsky Family Foundation together with his Liz. The aim of the Foundation is to fund the resources required in bettering arts and culture, healthcare, fundamental human rights, and education in the society. Click here to know more.
In a recent conference in San Diego, at the Fortune Brainstorm Health, Eric lefkofsky said that convalescent data was available, but there were insufficient sources that would combine both therapeutic data with genomic information. He also stated that today’s medical system lacked information about various things that are fundamental for cancer patients to get treatment successfully. Eric added that apart from collecting molecular information, clinical information is also essential. Additionally, doctors are required to have both therapeutic and outcome response information. Therefore other than RNA and DNA makeup, doctors should also have knowledge on which therapies they are on and how they are responding. Eric added that his aim was to get many individuals working on neurological disorders and those starting in oncology to use Tempus’ platform to collect data for analysis.